2 FTSE 100 stocks I’d buy before the ISA deadline for a starter portfolio

These FTSE 100 stocks offer a tempting mix of growth and income, argues Roland Head. He explains why he’d buy shares in both companies for a new Stocks and Shares ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Stocks and Shares ISA deadline is fast approaching on 5 April. Today, I want to look at two FTSE 100 stocks I’d buy ahead of the deadline for a starter share portfolio.

My analysis suggests both of these shares have the potential to deliver an attractive mix of income and growth over the coming years.

A 7% dividend yield I’d trust

My first pick is FTSE 100 insurance and retirement group Legal & General (LSE: LGEN). This £16bn company is familiar to most of us through products such as pensions or life insurance. But I think the real story is a bit more interesting than that.

Should you invest £1,000 in Glencore Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Glencore Plc made the list?

See the 6 stocks

Over the last decade or so, Legal & General boss Nigel Wilson has invested heavily in real assets such as renewable energy, commercial property, and data centres. The group is also investing in residential property.

On the whole, I think these assets have provided much stronger returns than more traditional financial investments, such as government bonds.

The only real risk I can see is that, for me as an outside investor, Legal & General is pretty much a black box. There’s no way I can understand the detail of its finances. I don’t know what impact falling property prices might have, for example. And I don’t know if the company’s assumptions about future income are reasonable.

What I do know is that results so far seem to support Wilson’s strategy. Legal & General’s profits have risen consistently in recent years. Unlike many rivals, it didn’t cut its dividend in 2020. Indeed, the company’s payout has risen by 33% to 17.8p per share since 2015, giving this FTSE 100 stock a 6.8% dividend yield.

My sums suggest Legal & General’s dividend looks pretty safe. I added the shares to my top-rated stocks and shares ISA account last year.

A 2-for-1 deal for a Stocks and Shares ISA

The other company I’d consider buying for a starter portfolio today is pharmaceutical group GlaxoSmithKline (LSE: GSK). Although the shares have traded sideways since 2013, things are about to change.

Later this year, this £80bn business will split itself in two. So-called New GSK will be a pure pharmaceutical business that’s focused on developing important new medicines.

Meanwhile, GlaxoSmithKline’s existing consumer healthcare division will be separated into a new company. This business owns brands such as Sensodyne, Panadol and Nicorette. In my view, it’s more of a consumer business like Unilever or Reckitt than a pharmaceutical operation.

I’m interested in owning shares in the consumer business. I’ve become even more bullish since GSK announced that former Tesco CEO ‘Drastic’ Dave Lewis will chair the new company. I think Lewis achieved excellent results at Tesco. I don’t think he’d take this role if he wasn’t confident he could do well again.

Of course, Glaxo’s future success isn’t guaranteed. Developing new medicines is a slow and expensive process that doesn’t always go to plan. The consumer business is likely to be lumbered with a lot of debt to start with, which could limit shareholder returns.

Even so, I believe GlaxoSmithKline shares offer good value today as a long-term investment. GSK would be on my shopping list if I was setting up a new portfolio in my Stocks and Shares ISA.

Of course, there are plenty of other passive income opportunities to explore. And these may be even more lucrative:

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns Legal & General Group and Unilever. The Motley Fool UK has recommended GlaxoSmithKline, Reckitt plc, Tesco, and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father and two young daughters dancing at home
Investing Articles

Just released: our 3 top small-cap stocks to consider buying in March [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

Shock news: the FTSE 100 is beating the S&P 500 and Nasdaq over one year!

Quite suddenly, the UK's FTSE 100 index has surged past the S&P 500 and Nasdaq Composite, beating both over one…

Read more »

Investing Articles

I asked ChatGPT to name 5 UK stocks for a perfectly balanced ISA – here’s what it picked! 

Harvey Jones is looking for UK stocks to add to this year's ISA, and decided to call in some assistance…

Read more »

Dividend Shares

With a 13.66% yield, is the FTSE 250’s largest dividend worth considering?

Jon Smith eyes up the highest yielding stock in the FTSE 250 at the moment, and balances out the risks…

Read more »

Investing Articles

Down 22%! Is this my chance to buy Nvidia stock?

Ben McPoland weighs up the case for and the case against reintroducing AI chip king Nvidia into his Stocks and…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Down 34%, are Greggs shares now a bargain?

Christopher Ruane looks at some pros and cons of buying Greggs' shares after the baker's valuation has taken a tumble…

Read more »

Electric cars charging at a charging station
Investing Articles

3 reasons why Tesla stock has crashed 39% in 2025

Our writer explores a trio of issues that have combined to negatively impact the Tesla (NASDAQ:TSLA) stock price so far…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Stocks to watch ahead of the Formula 1 season opener

Formula 1 has become big business since its US takeover. Here, Dr James Fox details a handful of stocks to…

Read more »